Published on in Vol 24, No 3 (2022): March

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/28978, first published .
Role of Telemedicine in Inflammatory Bowel Disease: Systematic Review and Meta-analysis of Randomized Controlled Trials

Role of Telemedicine in Inflammatory Bowel Disease: Systematic Review and Meta-analysis of Randomized Controlled Trials

Role of Telemedicine in Inflammatory Bowel Disease: Systematic Review and Meta-analysis of Randomized Controlled Trials

Journals

  1. Güney Coşkun M, Kolay E, Basaranoglu M. Telenutrition for the management of inflammatory bowel disease: Benefits, limits, and future perspectives. World Journal of Clinical Cases 2023;11(2):308 View
  2. Zouridis S, Ashraf M, Tempera P, Abulawi A, Malik U, Minhas H, Batool A. A Comparison of the Effects of COVID-19 on Irritable Bowel Syndrome and Inflammatory Bowel Disease Patients While Working at Home and in the Office: A Retrospective Study. Cureus 2023 View
  3. Gellad Z, Diamond S, Crockett S, Cross R. AGA Clinical Practice Update on Telemedicine in Gastroenterology: Commentary. Gastroenterology 2023;164(4):690 View
  4. Spartz E, DeDecker L, Le D, Jalilian L, Limketkai B. Advances in Mobile Health for Inflammatory Bowel Disease. Diagnostics 2022;13(1):37 View
  5. Shumskaya Y, Akhmedzyanova D, Mnatsakanyan M, Kolosova K, Tashchyаn O, Yurazh M, Reshetnikov R. Delphi method to determine a list of questionnaire-assessed parameters in the follow-up of patients with inflammatory bowel disease. Digital Diagnostics 2023;4(4):481 View
  6. Gravina A, Pellegrino R, Durante T, Palladino G, D'Onofrio R, Mammone S, Arboretto G, Auletta S, Imperio G, Ventura A, Romeo M, Federico A. Telemedicine in inflammatory bowel diseases: A new brick in the medicine of the future?. World Journal of Methodology 2023;13(4):194 View
  7. Gazizova Y, Bakirkhanov D, Nefedova T, Kostikova N, Akhmedzyanova D, Tashchyan O, Shumskaya Y, Mnatsakanyan M. Evaluation of the effectiveness of telemedical technologies in patients with digestive diseases. Digital Diagnostics 2023;4(1S):22 View
  8. Mathias H, Rohatinsky N, Murthy S, Novak K, Kuenzig M, Nguyen G, Fowler S, Benchimol E, Coward S, Kaplan G, Windsor J, Bernstein C, Targownik L, Peña-Sánchez J, Lee K, Ghandeharian S, Jannati N, Weinstein J, Khan R, Im J, Matthews P, Davis T, Goddard Q, Gorospe J, Latos K, Louis M, Balche N, Dobranowski P, Patel A, Porter L, Porter R, Bitton A, Jones J. The 2023 Impact of Inflammatory Bowel Disease in Canada: Access to and Models of Care. Journal of the Canadian Association of Gastroenterology 2023;6(Supplement_2):S111 View
  9. Fantini M, Loddo E, Di Petrillo A, Onali S. Telemedicine in inflammatory bowel disease from its origin to the post pandemic golden age: A narrative review. Digestive and Liver Disease 2024;56(1):1 View
  10. Elford A, Leong R, Halmos E, Morgan M, Kilpatrick K, Lewindon P, Gearry R, Christensen B. IBD barriers across the continents: a continent-specific analysis – Australasia. Therapeutic Advances in Gastroenterology 2023;16 View
  11. Akhmedzyanova D, Shumskaya Y, Mnatsakanyan M. Telemedical follow-up in patients with inflammatory bowel diseases. Digital Diagnostics 2023;4(1S):14 View
  12. Rohatinsky N, Russell B, Peña-Sánchez J, Boklaschuk S, Bhasin S, Fowler S, Guzowski T, Wicks K, Wicks M. Exploring the Experiences of Virtual Inflammatory Bowel Disease Care in Saskatchewan. Canadian Journal of Nursing Research 2024;56(1):95 View
  13. Gravina A, Pellegrino R, Cipullo M, Palladino G, Imperio G, Ventura A, Auletta S, Ciamarra P, Federico A. May ChatGPT be a tool producing medical information for common inflammatory bowel disease patients’ questions? An evidence-controlled analysis. World Journal of Gastroenterology 2024;30(1):17 View
  14. Echarri A, Pradera C, Molina G, Gonzalez Moure C, De las Heras C, Fraga Iriso R, Ollero V, Echevarria C, Muñiz J. Implementation of a Teledermatology Electronic Consultation Program to Improve the Care of Patients with Inflammatory Bowel Disease. Telemedicine Reports 2024;5(1):12 View
  15. Ghodasara S, Roskam J, Uretsky M, Chang G, Rolandelli R, Nemeth Z. Effects of the COVID-19 Pandemic on Colectomy Outcomes for Inflammatory Bowel Disease. Southern Medical Journal 2024;117(2):88 View
  16. Venuturupalli S, Peck A, Jinka Y, Fortune N, Davuluri N, Nowell W, Gavigan K, Cush J, Soares N, Grainger R, Curtis J. Home‐Based Telemedicine in Rheumatology—A Scoping Review. ACR Open Rheumatology 2024;6(5):312 View
  17. Zhang X, Ma L, Sun D, Yi M, Wang Z. Artificial Intelligence in Telemedicine: A Global Perspective Visualization Analysis. Telemedicine and e-Health 2024 View
  18. Hakak F, Patel R, Gearry R. Review article: Telecare in gastroenterology—Within the COVID‐19 pandemic and beyond. Alimentary Pharmacology & Therapeutics 2024;59(10):1170 View
  19. San E, Egberts A, van Dijck - van Boetzelaer C, West R, Vasbinder E. High refill-adherence to adalimumab is associated with low disease activity in patients with inflammatory bowel disease. European Journal of Clinical Pharmacology 2024;80(7):1089 View
  20. Trandafir L, Spoiala E, Ghiga G, Gimiga N, Budescu P, Lupu V, Butnariu L, Cojocaru E, Paduraru G. Impact of COVID-19 on Pediatric Inflammatory Bowel Diseases—From Expectations to Reality. Journal of Personalized Medicine 2024;14(4):399 View
  21. Ren C, Zhou Y, Cai Q, Zhou M. Summary of the best evidence on self-management support schemes for patients with inflammatory bowel disease based on mobile health systems. DIGITAL HEALTH 2024;10 View
  22. Ludeña-Poma J, Rojas-Gallegos S, Solano-Ortiz L, Castro-Chavez Y, Chahua-Borda D, Ludeña-Poma J. Influence of resistance to use, perceived ease of use, perceived usefulness, and facilitating conditions in the intention to use telemedicine in Peru. Pharmacia 2024;71:1 View